Biocon Ltd. (BION)

Currency in INR
399.70
+1.55(+0.39%)
Real-time Data·
BION Scorecard
Full Analysis
Trading at a high earnings multiple
BION is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
397.60401.00
52 wk Range
291.00406.00
Key Statistics
Bid/Ask
399.75 / 399.80
Prev. Close
398.15
Open
400
Day's Range
397.6-401
52 wk Range
291-406
Volume
492.5K
Average Volume (3m)
4.69M
1-Year Change
10.03%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BION Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
382.90
Downside
-4.20%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

Biocon Ltd. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Biocon Ltd. Company Profile

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Employees
16315
Market
India

Compare BION to Peers and Sector

Metrics to compare
BION
Peers
Sector
Relationship
P/E Ratio
52.4x34.1x−0.5x
PEG Ratio
−55.971.220.00
Price/Book
2.5x5.1x2.6x
Price / LTM Sales
3.5x4.6x3.2x
Upside (Analyst Target)
0.5%2.3%42.0%
Fair Value Upside
Unlock−1.1%6.6%Unlock

Analyst Ratings

11 Buy
3 Hold
5 Sell
Ratings:
19 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 382.90
(-4.20% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.46%
Dividend Yield
0.13%
Industry Median 0.17%
Annualised payout
0.50
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 08, 2025
EPS / Forecast
2.81 / 1.71
Revenue / Forecast
44.17B / 41.82B
EPS Revisions
Last 90 days

BION Income Statement

People Also Watch

389.35
BAJE
+0.28%
250.50
ADTB
-0.73%
7,452.50
APLH
-0.05%
2,166.60
GLEN
+0.40%
410.80
PWFC
+0.05%

FAQ

What Stock Exchange Does Biocon Trade On?

Biocon is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for Biocon?

The stock symbol for Biocon is "BION."

What Is the Biocon Market Cap?

As of today, Biocon market cap is 533.77B.

What Is Biocon's Earnings Per Share (TTM)?

The Biocon EPS (TTM) is 8.46.

When Is the Next Biocon Earnings Date?

Biocon will release its next earnings report on 22 Oct 2025.

From a Technical Analysis Perspective, Is BION a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Biocon Stock Split?

Biocon has split 3 times.

How Many Employees Does Biocon Have?

Biocon has 16315 employees.

What is the current trading status of Biocon (BION)?

As of 30 Jul 2025, Biocon (BION) is trading at a price of 399.70, with a previous close of 398.15. The stock has fluctuated within a day range of 397.60 to 401.00, while its 52-week range spans from 291.00 to 406.00.

What Is Biocon (BION) Price Target According to Analysts?

The average 12-month price target for Biocon is INR382.9, with a high estimate of INR447 and a low estimate of INR270. 11 analysts recommend buying the stock, while 5 suggest selling, leading to an overall rating of Buy. The stock has an -4.20% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.